GATA3 Truncation Mutants Alter EMT Related Gene Expression
GATA-3
GATA3
breast cancer
epithelial-to-mesenchymal transition
luminal breast cancer
somatic mutations
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
11
2021
accepted:
10
01
2022
entrez:
14
2
2022
pubmed:
15
2
2022
medline:
15
2
2022
Statut:
epublish
Résumé
GATA3 is known to be one of the most frequently mutated genes in breast cancer. More than 10% of breast tumors carry mutations in this gene. However, the functional consequence of GATA3 mutations is still largely unknown. Clinical data suggest that different types of GATA3 mutations may have distinct roles in breast cancer characterization. In this study, we have established three luminal breast cancer cell lines that stably express different truncation mutants (X308 splice site deletion, C321 frameshift, and A333 frameshift mutants) found in breast cancer patients. Transcriptome analysis identified common and distinct gene expression patterns in these GATA3 mutant cell lines. In particular, the impacts on epithelial-to-mesenchymal transition (EMT) related genes are similar across these mutant cell lines. Chromatin localization of the mutants is highly overlapped and exhibits non-canonical motif enrichment. Interestingly, the A333 frameshift mutant expressed cells displayed the most significant impact on the GATA3 binding compared to X308 splice site deletion and C321fs mutants expressed cells. Our results suggest the common and different roles of GATA3 truncation mutations during luminal breast cancer development.
Identifiants
pubmed: 35154280
doi: 10.3389/fgene.2022.820532
pii: 820532
pmc: PMC8831884
doi:
Types de publication
Journal Article
Langues
eng
Pagination
820532Informations de copyright
Copyright © 2022 Saotome, Poduval, Nair, Cooper and Takaku.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Cell Res. 2014 Jul;24(7):809-19
pubmed: 24874954
Oncogene. 1999 Jul 1;18(26):3905-12
pubmed: 10445855
Nucleic Acids Res. 2020 May 21;48(9):4756-4768
pubmed: 32232341
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Nat Commun. 2018 Sep 4;9(1):3476
pubmed: 30181556
Cell. 1997 May 16;89(4):587-96
pubmed: 9160750
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17460-5
pubmed: 23033492
Cancer Lett. 2016 Jun 28;376(1):104-9
pubmed: 27018307
Nucleic Acids Res. 2018 Jan 4;46(D1):D661-D667
pubmed: 29136241
Int J Cancer. 1999 Apr 20;84(2):122-8
pubmed: 10096242
Genome Res. 2013 Jan;23(1):12-22
pubmed: 23172872
Oncogene. 2007 Dec 13;26(57):7859-71
pubmed: 17603561
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Bioinformatics. 2011 Jun 15;27(12):1696-7
pubmed: 21486936
Gene Expr. 2015;16(4):163-8
pubmed: 26637396
Nat Cell Biol. 2020 Jun;22(6):701-715
pubmed: 32424275
Cell. 2016 Sep 22;167(1):260-274.e22
pubmed: 27641504
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Mol Syst Biol. 2011 Aug 30;7:526
pubmed: 21878914
J Exp Med. 2019 May 6;216(5):1016-1026
pubmed: 30975895
Cancer Res. 2005 Dec 15;65(24):11259-64
pubmed: 16357129
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
pubmed: 12829800
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Genome Biol. 2014;15(12):550
pubmed: 25516281
Hum Genet. 2002 Oct;111(4-5):411-20
pubmed: 12384785
Nature. 2019 May;569(7757):560-564
pubmed: 31118521
Oncogene. 2004 Oct 7;23(46):7669-78
pubmed: 15361840
BMC Cancer. 2014 Apr 22;14:278
pubmed: 24758297
PLoS Genet. 2016 Sep 02;12(9):e1006279
pubmed: 27588951
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
J Cell Physiol. 2010 Jan;222(1):42-9
pubmed: 19798694
Anticancer Res. 2018 Aug;38(8):4435-4441
pubmed: 30061207
Cell. 2006 Dec 1;127(5):1041-55
pubmed: 17129787
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
BMC Med. 2015 Oct 15;13:266
pubmed: 26467651
BMC Cancer. 2017 Jun 26;17(1):447
pubmed: 28651527
Nat Commun. 2018 Mar 13;9(1):1059
pubmed: 29535312
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Oncotarget. 2017 Oct 20;8(61):103415-103427
pubmed: 29262572
Oncogene. 2020 Aug;39(32):5455-5467
pubmed: 32587399
Nat Cell Biol. 2013 Feb;15(2):201-13
pubmed: 23354167
Cell. 2015 Oct 8;163(2):506-19
pubmed: 26451490
Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2269-75
pubmed: 18006915